All the news Showing 10 of 135 articles from: Interferon-free regimensGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Achillion Reports 100% SVR12 in a Phase 2 Combination Study With ACH-3102 at the Liver Meeting 2014 (AASLD) Achillion press release / 10 November 2014 ALLY Trial Demonstrates High Cure Rates for Investigational Daclatasvir and Sofosbuvir Combination among Genotype 3 Hepatitis C Patients Bristol-Myers Squibb press release / 10 November 2014 Merck's Four-Week Hepatitis C Regimen Fails to Top Gilead Bloomberg / 10 November 2014 Olysio (simeprevir) approved for use in combination with sofosbuvir Johnson & Johnson press release / 07 November 2014 FDA approves first combination pill to treat hepatitis C FDA / 22 October 2014 Fair Pricing Coalition Urges a Uniform Price for Curative Hepatitis C Treatment Fair Pricing Coalition / 15 October 2014 European CHMP Adopts Positive Opinion for Gilead’s Harvoni® (Ledipasvir/Sofosbuvir) for the Treatment of Chronic Hepatitis C Infection in Adults Gilead press release / 29 September 2014 The new $84,000 hepatitis C treatment is losing momentum, for now Washington Post / 22 September 2014 Japan Approves First All-Oral, Interferon- and Ribavirin-Free Hepatitis C Treatment, Daklinza® (daclatasvir) and Sunvepra® (asunaprevir) Dual Regimen Bristol-Myers Squibb press release / 08 July 2014 Daclatasvir + asunaprevir is highly effective against hepatitis C genotype 1b HIVandHepatitis.com / 13 June 2014 ← Prev1...34567...14Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive